BACKGROUND: Chronic obstructive pulmonary disease (COPD) is prevalent in nursing home residents. National and international guidelines exist for management of COPD; however, little is known about "real-world" management of COPD in this population. Nursing home patients with significant cognitive impairment may have difficulty utilizing handheld device (HHD) formulations of respiratory medications and may be clinically appropriate candidates for nebulized therapy.
• Little is known about the way that chronic obstructive pulmonary disease (COPD) medications are utilized in nursing home residents. Given the prevalence of Alzheimer's disease and nonAlzheimer's dementia in nursing homes, cognitive and physical function is moderately to severely impaired. Allen et al. (2009) noted that subjects older than 70 years of age with moderate dementia were unable to learn and coordinate 3 stages of inhalation techniques using metered dose inhalers.
• COPD has been identified as one of 5 conditions responsible for potentially avoidable hospitalizations in nursing home residents (Walsh et al. 2012 ). Age > 70 years has been associated with increased all-cause hospitalization and high financial burden in Medicare beneficiaries with COPD patients residing in nursing homes.
• Monotherapy with short-acting beta-agonists for management of COPD is discouraged in the Global Initiative for Chronic Obstructive Lung Disease guidelines.
What is already known about this subject
• Consequences of nebulized short-acting beta-agonists (SABA) monotherapy in nursing home residents have not been previously characterized. This study indicates that shortness of breath (SOB) and exacerbations are common in this population and may be related to use of SABA in the absence of long-acting beta-agonists (LABA) or long-acting anticholinergic agents. Between 33.9% and 39.8% of patients with moderate to very severe cognitive impairment treated with SABA monotherapy exhibited SOB. Additionally, 17% of patients with a diagnosis of COPD received no medications. Chronic Obstructive Pulmonary Disease: Prevalence, Characteristics, and Pharmacologic Treatment in Nursing Home Residents with Cognitive Impairment majority of which was moderate to severe, 6 while 2009 data showed that 47% of all nursing home patients had a diagnosis of Alzheimer's disease or other dementia in the nursing home record. 7 The standardized assessment tool for patients in nursing facilities, the Minimum Data Set (MDS) version 2.0, contains individual items that can identify patients with cognitive impairment. 8 The Cognitive Performance Scale (CPS) score is a measure of cognition that is calculated from 5 unique MDS version 2.0 items (item B1: Comatose; item B2a: Short-Term Memory; item B4: Cognitive Skills for Daily Decision Making; item C4: Making Self Understood; and item G1ha: Eating). The CPS has been shown to have a significant positive correlation with the Mini-Mental State Examination (MMSE) and is scored on a 0-6 scale, with 0 corresponding to No Impairment (intact) and 6 corresponding to Very Severe Impairment. [9] [10] [11] Nursing home patients with significant cognitive impairment may have difficulty utilizing handheld device (HHD) formulations (metered-dose or dry powder inhalers) of COPD medications and may be clinically appropriate candidates for nebulized therapy. 12 The objective of this study was to develop a "profile" of patients in nursing homes with a diagnosis of COPD, including but not limited to pertinent demographic information, concurrent diagnoses, medications used in the treatment of COPD, other concomitant medications, and numerous functional (e.g., ability to ambulate independently) and quality of life (e.g., oxygen use) parameters extracted from the MDS and pharmacy claims data. Further, we sought to determine the relationship of short-acting beta-agonists (SABA) versus long-acting betaagonists (LABA) and handheld devices (HHD) versus nebulized medication use to prevalence of shortness of breath (SOB) in a cohort of cognitively impaired nursing home residents.
What this study adds

■■ Methods
The MDS is a comprehensive, standardized resident assessment instrument that is utilized in nursing facilities to develop care delivery and planning; monitor clinical indicators such as falls, fractures, cognition, and behavior; and determine payment from Medicare. The MDS assessment is conducted for all residents of nursing facilities upon admission, quarterly, annually, and when the resident has a significant change in status. Version 2.0 of the MDS was used for this study. The MDS data elements have been validated, and there is evidence for interrater reliability. 13 Over 85% of MDS data elements have been found to be reliable with adequate inter-rater reliability and overall good agreement. 13, 14 The strongest reliability was with elements related to activities of daily living (ADL). ADL, pain, distressed mood, behavioral disturbances, and social engagement elements of the MDS have manifested discriminant validity. 15 Validity problems have been reported with MDS data T he prevalence of chronic obstructive pulmonary disease (COPD) in the nursing home setting is approximately 10%-20%. 1 The Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD), the American Medical Directors Association (AMDA) Clinical Practice Guidelines, and the guidelines by the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society recommend the use of longacting beta-agonists and/or anticholinergics for management of patients with moderate and more severe COPD. [2] [3] [4] Among nursing home patients with COPD, there is variation in the medication class, route of administration, and formulation used to treat this condition. For example, some patients require nebulized therapy due to comorbidities or functional impairment, while others prefer the nebulized route of administration for these medications because they feel they are more effective. 5 The GOLD and AMDA guidelines recommend a stepwise approach to therapy for patients with COPD.
2,3 While shortacting bronchodilators are recommended on a "when needed" basis beginning in mild disease and throughout the course of the disease, the addition of routine treatment with 1 or more long-acting bronchodilators should occur beginning in moderate disease, and inhaled corticosteroids should be added for those with severe or very severe disease if repeated exacerbations occur. The addition of long-term oxygen therapy is recommended for those with very severe disease. [2] [3] [4] For exacerbations of COPD, the GOLD and AMDA guidelines recommend increasing the dose or frequency of short-acting inhaled bronchodilators, considering short-course systemic corticosteroid therapy, and utilizing short-term antibiotic therapy for patients with clinical signs of airway infection, such as increased sputum purulence.
The multiple medical conditions, complicated medication regimens, and high prevalence of cognitive impairment add to the challenge of the risk-benefit assessment that clinicians face when treating COPD in nursing home patients. It is estimated that between 50% and 70% of patients in nursing facilities have some degree of dementia. In 2008, 68% of all nursing home patients had some degree of cognitive impairment, the • Twenty-two percent of nursing home residents with COPD experienced at least 2 exacerbations of COPD, and as many as 60% were not receiving a long-acting agent. Over 55% were hospitalized at least once, and 11.3% had at least 1 emergency room visit.
• Nebulization is a common route of administration for respiratory medications in nursing home residents independent of their cognitive function. Thirty-nine percent of residents with moderate to very severe cognitive impairment received SABA monotherapy. elements of visual acuity, pain frequency and intensity, and resident incontinence, all of which were excluded as measures of interest for this study. 15 The instrument has been criticized by some for data discrepancies that occur due to miscoding. Agreement rates for a number of data elements have been reportedly poor but reliability adequate when calculated using a weighted kappa statistic.
What this study adds (continued)
14 While there are limitations to this caregiver-related assessment instrument, it is a standardized tool that provides the "best available evidence" of resident status and outcomes in the nursing facility setting.
Information for this study was gleaned from Omnicare Senior Health Outcomes (OSHO) Data Warehouse of resident records (demographic and admission tables), resident MDS records, prescription records, drug data and prescriber specialty records, facility records, and prescriber records. Most of the data in the OSHO Data Warehouse is refreshed on a daily basis, with the exception of resident MDS records and drug data records (data dictionary).
The real-time data is collected from about 200 pharmacies serving more than 1.4 million residents in about 19,000 longterm care and other health care facilities in 48 states (excludes Hawaii and Alaska) and Canada. The database stores over 600 million pharmacy (Rx) claims processed within the last 6 years. All de-identifiable datasets carry a unique resident identification key that allows longitudinal tracking at the prescription claims level. The prescription data can be analyzed by National Drug Code (NDC), brand name, strength, dosage form, individual ingredient, and drug therapeutic class. Resident MDS records are available for residents in facilities that use the AccuMed electronic MDS system, a small subset (estimated to be 10%-15%) of the residents within the Omnicare network.
Within the OSHO Data Warehouse are 2 datasets: pharmacy claims data for residents in Omnicare-serviced nursing homes and MDS data for residents in nursing homes that are clients of AccuMed's electronic MDS application. Omnicare is the owner of the pharmacy claims data and a processor of the MDS data. To perform the data match, prescription claims data were obtained from the warehouse, and MDS data were obtained from the warehouse for the time period of October 1, 2009, through September 30, 2010. Once the 2 datasets were extracted, they were matched using resident demographics. Then, the matched records were de-identified using a "safe harbor" method in which all 18 identifiable data elements listed in section 164.514(b)(2) of the HIPAA Privacy Rule were removed and replaced with internal identifiers. The internal identifier is a randomly generated number that is not derived from or related to the information about the individual and is not otherwise capable of being translated to identify the individual. In addition, all internal identifiers were encrypted using a 128-bit, one-way hashing algorithm to further ensure that identifiers cannot be traced to individuals. Figure 1 depicts the patient selection algorithm for this study. Initially, a count of unique patients for whom MDS data existed in the database was obtained and served as the denominator for determining the prevalence of COPD. The diagnosis of emphysema/COPD was made if the presence was noted on MDS item I1.ii and asthma if so noted by item I1.hh. The unique number of patients with a diagnosis of COPD in MDS records (n = 27,106) was then used as the denominator for all nonmedication-related calculations. However, for the medication data, the denominator used was the total number of unique patients with a diagnosis of COPD in MDS records who had at least 1 pharmacy claim (n = 20,978). Not all residents with a diagnosis of COPD received treatment with respiratory medications, despite having other prescription claims in the OSHO Data Warehouse. Additionally, not all residents with a diagnosis of COPD had their medications supplied by Omnicare. Therefore, in order to calculate the percentage of treated patients, the denominator of patients for whom pharmacy records are available (n = 20,978) was used.
For patients who had more than 1 MDS assessment during the 12-month study period, MDS results were compared, and the answer representing the more severe condition was used. For example, if MDS item C1 (hearing) was scored a 0 ("hear adequately") in one assessment and 2 ("hear in special situations only") in another, then the latter score was used for that patient.
SOB was defined by positive selection of J1.b and J1l on the MDS. An exacerbation of COPD was defined as an episode in which a patient received either a short course (≤ 14 days) of "respiratory" antibiotics 16 or oral corticosteroids or both. We calculated the percentage of patients with 2 or more exacerbations in 12 months. Respiratory antibiotics, identified by First DataBank's specific therapeutic classification (GC3), were denoted as azithromycin, levofloxacin, moxifloxacin, amoxicillin/clavulanate, doxycycline, cefuroxime, cefdinir, cefpodoxime, gemifloxacin, amoxicillin, trimethoprim-sulfamethoxazole, clarithromycin, cefprozil, cefditoren, cefepime, ceftazidime, imipenem/cilastatin, meropenem, piperacillin/tazobactam, vancomycin (parenteral only), linezolid, gentamincin, tobramycin, and amikacin for the purposes of this investigation. Descriptive statistics were performed for all data fields.
■■ Results
The total number of unique patients with at least 1 MDS assessment during the study period was 126,121. Of those, a total of 27,106 unique patients had a diagnosis of COPD indicated on MDS records, resulting in a COPD prevalence of 21.5%.
Concurrent Diagnoses
In patients with a diagnosis of COPD, the prevalence of an asthma diagnosis per MDS records was 8.6%; Alzheimer's disease or other dementia was 37.2%, congestive heart failure 37.5%, anxiety disorder 23%, depression 50.1%, pneumonia 21.2%, and respiratory infection 9% (Table 1) .
Demographic and Clinical Profile from Minimum Data Set
Demographically, the majority of patients with a diagnosis of COPD were white females (82%, 58.4%, respectively) and aged 75 years or older (64.7%). Approximately 16% of patients were between the ages of 75-79 years; the prevalence of those 80-84 years, 85-89 years, and 90 years or older was 19.2%, 17.5%, and 12.1%, respectively. Blacks made up 9.8% of the COPD population, while Hispanics accounted for 5% of patients. In the year prior to admission, tobacco products were used at least daily in 9.4% of patients.
Clinically, 62% of COPD patients had a short-term memory problem, while 43.3% of patients had moderately or severely impaired cognitive skills for daily decision making (Table 2) . This is in agreement with CPS scores for the study sample in which 41.8% of patients had CPS scores of 3-6, indicating moderate to very severe impairment. Conversely, nearly 60% of patients with COPD had none-to-mild cognitive (Figure 2) , with greater than 65% of patients requiring extensive assistance or noted to be totally dependent on staff assistance in the areas of bed mobility, transfer, dressing, and personal hygiene. Twenty-four percent of patients required extensive assistance or were totally dependent on staff for assistance with eating.
Related specifically to COPD symptomatology, one-third of patients were noted to have SOB, and 12.4% of patients were unable to lie flat due to SOB. Additionally, 52.8% of patients required oxygen therapy; however, only 10.1% received respiratory therapy services. Comorbidities commonly associated with COPD were highly prevalent in these patients, including depression (50.1%), anemia (30.9%), diabetes mellitus (39.8%), Chronic Obstructive Pulmonary Disease: Prevalence, Characteristics, and Pharmacologic Treatment in Nursing Home Residents with Cognitive Impairment common than SABA (15.1%) and short-acting anticholinergic (1.9%) medications delivered via HHD. Using less than or equal to 14-day courses of respiratory antibiotics, oral corticosteroids, or both as a proxy for an acute exacerbation of COPD, there were 5,085 of 23,022 unique COPD patients (22.1%) with 2 or more exacerbations. Table 4 depicts the percentage of patients with moderate to very severe cognitive impairment receiving monotherapy with SABA, LABA, or the combination in HHD and nebulized formulations with the corresponding presence of SOB, exacerbations, and hospitalizations. In the 48.7% of cognitively impaired patients that received SABA monotherapy, SOB was noted in 39.1%, while 59.1% had 1 or more hospitalizations over the 12-month period. Nebulized SABA monotherapy was the most common form of COPD treatment in these cognitively impaired individuals. Patients receiving LABA monotherapy were less likely to have SOB (25%) or an exacerbation (26.9%), but the number of patients receiving LABA monotherapy is too small to draw conclusions.
MDS Data Element Total Number Percentage
■■ Discussion
This is a real-world look into the clinical characteristics and treatment of nursing home residents with COPD. Because of the frailty, underlying concomitant illness, and prevalence of cognitive impairment of patients in this health care setting, treatment decisions are based commonly on information deduced from family, medical records, facility staff, and the MDS data. While portable spirometry can be performed in the nursing home, based on the limitations in accuracy of and congestive heart failure (37.5%). Although osteoporosis is known to be associated with COPD, only 16.6% of patients had this diagnosis in MDS records. Osteoporosis and possible skeletal muscle dysfunction (which is not captured in MDS data) may have contributed to the prevalence of falls (70.3% of patients within a 180-day period) and fractures (13.7% of patients within a 180-day period) that were noted. A weight loss of 5% or more in the previous 30 days or 10% or more in the previous 180 days was noted in 21.5% of patients, while 13.3% had a corresponding weight gain.
Regarding the overall stability of conditions for the patients with COPD, 47.9% were noted to be experiencing an acute episode or flare-up of a recurrent or chronic problem, although the MDS does not specify the exact nature of the acute problem. Nearly 5 percent (4.5%) of patients with COPD were noted to be end stage (defined as 6 or fewer months to live). The diseases responsible for this end-stage designation were not captured by MDS data. Finally, during the study period, 47.8% of patients required 1 hospital stay; 6.7% required 2 hospital stays; and 9.8% required at least 1 emergency room visit.
Medication Use
Among the 27,106 unique patients with a diagnosis of COPD, 17,395 (82.9%) received at least 1 medication used to treat COPD. Those patients with a diagnosis of COPD who received no respiratory medications for this condition numbered 9,711 (17.1%). Table 3 provides a summary of medication use.
The use of nebulized dosage forms of SABA (48.6%) and short-acting anticholinergic (23.4%) medications was more 
Percentage of Long-Term Care Patients Requiring Extensive Assistance or Totally Dependent for Activities of Daily Living
Activities of Daily Living
Chronic Obstructive Pulmonary Disease: Prevalence, Characteristics, and Pharmacologic Treatment in Nursing Home Residents with Cognitive Impairment moderate to moderately high validity and reliability. 21 The linking of these datasets allows investigators to ask questions that can be viewed as hypothesis generating for future studies rather than conclusive or causative.
Unfortunately, the degree of pulmonary functional or symptomatic impairment cannot be quantified using administrative data only. Thus, disease severity cannot be evaluated as a variable affecting product choice in these patients. Furthermore, disease staging through spirometry has limitations in frail elderly adults for whom respiratory effort can be severely compromised and lung volumes reduced. 12 spirometry in this population, diagnosis is usually based on symptoms and history. 17 In light of these considerations, a real-world investigation performed retrospectively using a large data repository contributes substantial information about the management of COPD in nursing home residents.
This analysis revealed that 21.5% of nursing home residents had a diagnosis of COPD, and 17% of those with COPD received no respiratory medications. Our sample depicts a population with significant cognitive and functional impairment, serious comorbid illness, and the presence of conditions that make the patient's cognition, functionality, mood, or behavior unstable. At least 20% of residents treated for COPD experienced at least 2 acute exacerbations of COPD during the 12 months of study, and as many as 60% were not receiving long-acting beta-agonist/corticosteroid (LABA/ICS) HHD combination therapy. Despite the prevalence of exacerbations requiring treatment with a respiratory antibiotic or respiratory antibiotic and oral corticosteroid, only 5,863 patients (28%) received inhaled LABA/ICS combination therapy as recommended by the GOLD and AMDA guidelines. 2, 3 Along with Pleasants (2009), we found that more than a quarter of nursing home residents with COPD have comorbidities such as cardiovascular disease, diabetes, osteoporosis, and dementia complicating their treatment and adding to the burden of illness. 1 The results of a quality improvement project identified COPD as one of the most prevalent conditions leading to 7-day and 30-day hospital readmission rate of 23% in a sample of patients discharged from a community hospital to a nursing home. 18 Simoni-Wastila et al. (2009), using a retrospective analysis of a large administrative claims database, reported that 43.3% of long-term care residents with COPD had at least 1 hospitalization, and 90% had at least 1 emergency room visit. 19 Age greater than 70 years was associated with an increase in all-cause hospitalization and increased burden of illness. COPD has recently been identified as 1 of 5 conditions associated with potentially avoidable hospital admissions of dually eligible Medicaid and Medicare beneficiaries, 20%-60% of which could be prevented.
20
Limitations
The limitations of this study are characteristic of retrospective database analyses. Claims prescription data accurately reflect dispensed medications as they are adjudicated online and represent information 6 months or longer post-reconciliation. However, not all patients received their medications from Omnicare, and medication consumption may be overrepresented, using prescription claims data in nursing home residents who may refuse or spit out doses, resulting in waste. There are potential inaccuracies in coding of MDS data due to poor medical historical data and inter-rater variability. When reviewed by others, MDS data have been reported to have Lastly, the use of short-course antibiotic and/or corticosteroid therapy as a proxy for COPD exacerbations may overestimate the actual number of exacerbations given that these therapies are prescribed for other indications as well. In our search of the literature, we could find no similar studies of nursing home residents with COPD and view an understanding of these findings as a necessary first step in improving the quality of care and reducing COPD exacerbations in this population. Despite the potential limitations described, this real-world examination provides meaningful insight regarding several key observations.
■■ Conclusions
Nursing home patients with COPD and cognitive impairment are a special population for whom optimal management of COPD is challenging. Monotherapy with HHDs or nebulized SABAs is prevalent and can be a sign of, or contributor to, unstable disease that may help explain SOB in nearly onethird of all treated patients and COPD exacerbations in 22.1% of patients. Undertreatment with a LABA, whether by HHD or nebulization in those with moderately severe or severe cognitive impairment, was evident.
In this population of patients with moderately severe and severe cognitive impairment, nebulized LABA, long-acting inhaled anticholinergic, and the combination of LABA/ICS therapy should be considered to align treatment with practice guidelines, reduce the prevalence of SOB, and reduce COPD exacerbations. 
